O-GlcNAcylation in Ovarian Tumorigenesis and Its Therapeutic Implications

Overview

Journal Transl Oncol

Specialty Oncology

Date 2024 Dec 1

PMID 39616984

Authors

Lu Xia

Jie Mei

Min Huang

Dandan Bao

Zhiwei Wang

Yizhe Chen

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is a prevalent malignancy among women, often associated with a poor prognosis. Post-translational modifications (PTMs), particularly O-GlcNAcylation, have been implicated in the progression of ovarian cancer. Emerging evidence indicates that dysregulation of O-GlcNAcylation contributes to the initiation and malignant progression of ovarian cancer. This review discusses the potential role of O-GlcNAcylation in ovarian tumorigenesis, with a focus on its regulation of various cellular signaling pathways, including p53, RhoA/ROCK/MLC, Ezrin/Radixin/Moesin (ERM), and β-catenin. This review also emphasizes the O-GlcNAcylation of critical proteins in ovarian cancer, such as SNAP-23, SNAP-29, E-cadherin, and calreticulin. Additionally, the potential of O-GlcNAcylation to enhance immunotherapy for ovarian cancer patients is explored. Several compounds targeting OGT and OGA in ovarian cancer are also highlighted. Targeting the dynamic and versatile nature of O-GlcNAcylation could undoubtedly contribute to more effective treatments and improved outcomes for ovarian cancer patients.

References

Yang Y, Zhou X, Deng H, Chen L, Zhang X, Wu S . The role of O-GlcNAcylation in bone metabolic diseases. Front Physiol. 2024; 15:1416967. PMC: 11194333. DOI: 10.3389/fphys.2024.1416967. View

Ohta T, Takahashi T, Shibuya T, Amita M, Henmi N, Takahashi K . Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells. Cancer Biol Ther. 2012; 13(1):25-33. DOI: 10.4161/cbt.13.1.18440. View

Sun J, Mu H, Dai K, Yi L . Calreticulin: a potential anti-cancer therapeutic target. Pharmazie. 2018; 72(9):503-510. DOI: 10.1691/ph.2017.7031. View

Cai H, Xiong W, Zhu H, Wang Q, Liu S, Lu Z . Protein O-GlcNAcylation in multiple immune cells and its therapeutic potential. Front Immunol. 2023; 14:1209970. PMC: 10477433. DOI: 10.3389/fimmu.2023.1209970. View

Wang W, Liu W, Chen Q, Yuan Y, Wang P . Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy. Semin Cancer Biol. 2022; 87:84-97. DOI: 10.1016/j.semcancer.2022.11.002. View

Ma G, Lin W . Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy. Mil Med Res. 2023; 10(1):20. PMC: 10142459. DOI: 10.1186/s40779-023-00455-x. View

Schcolnik-Cabrera A, Juarez M, Oldak B, Cruz-Rivera M, Flisser A, Duenas-Gonzalez A . In Vitro Employment of Recombinant Taenia solium Calreticulin as a Novel Strategy Against Breast and Ovarian Cancer Stem-like Cells. Arch Med Res. 2020; 51(1):65-75. DOI: 10.1016/j.arcmed.2019.12.003. View

Vasquez Martinez I, Perez-Campos E, Perez-Campos Mayoral L, Cruz Luis H, Pina Canseco M, Zenteno E . O-GlcNAcylation: Crosstalk between Hemostasis, Inflammation, and Cancer. Int J Mol Sci. 2024; 25(18). PMC: 11432004. DOI: 10.3390/ijms25189896. View

You Z, Peng D, Cao Y, Zhu Y, Yin J, Zhang G . P53 suppresses the progression of hepatocellular carcinoma via miR-15a by decreasing OGT expression and EZH2 stabilization. J Cell Mol Med. 2021; 25(19):9168-9182. PMC: 8500955. DOI: 10.1111/jcmm.16792. View

10.

Liu J, Chen T, Li S, Liu W, Wang P, Shang G . Targeting matrix metalloproteinases by E3 ubiquitin ligases as a way to regulate the tumor microenvironment for cancer therapy. Semin Cancer Biol. 2022; 86(Pt 2):259-268. DOI: 10.1016/j.semcancer.2022.06.004. View

11.

Tameishi M, Ishikawa H, Tanaka C, Kobori T, Urashima Y, Ito T . Ezrin Contributes to the Plasma Membrane Expression of PD-L1 in A2780 Cells. J Clin Med. 2022; 11(9). PMC: 9100183. DOI: 10.3390/jcm11092457. View

12.

Lu Q, Zhang X, Liang T, Bai X . O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy. Mol Med. 2022; 28(1):115. PMC: 9476278. DOI: 10.1186/s10020-022-00544-y. View

13.

Song M, Suh P . O-GlcNAcylation regulates lysophosphatidic acid-induced cell migration by regulating ERM family proteins. FEBS Open Bio. 2022; 12(6):1220-1229. PMC: 9157403. DOI: 10.1002/2211-5463.13404. View

14.

Wang Y, Fang X, Wang S, Wang B, Chu F, Tian Z . The role of O-GlcNAcylation in innate immunity and inflammation. J Mol Cell Biol. 2022; 14(9). PMC: 9951266. DOI: 10.1093/jmcb/mjac065. View

15.

Wang Y, Sheng Q, Spillman M, Behbakht K, Gu H . Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. Oncogene. 2011; 31(20):2512-20. PMC: 3262088. DOI: 10.1038/onc.2011.435. View

16.

Zhang J, Wang Y . Emerging roles of O-GlcNAcylation in protein trafficking and secretion. J Biol Chem. 2024; 300(3):105677. PMC: 10907171. DOI: 10.1016/j.jbc.2024.105677. View

17.

Shen L, Zhang W, Deng J, Qi Z, Lin Z, Wang Z . Advances in the mechanism of small nucleolar RNA and its role in DNA damage response. Mil Med Res. 2024; 11(1):53. PMC: 11308251. DOI: 10.1186/s40779-024-00553-4. View

18.

Yang J, Song C, Zhan X . The role of protein acetylation in carcinogenesis and targeted drug discovery. Front Endocrinol (Lausanne). 2022; 13:972312. PMC: 9510633. DOI: 10.3389/fendo.2022.972312. View

19.

Wu C, Li J, Lu L, Li M, Yuan Y, Li J . OGT and OGA: Sweet guardians of the genome. J Biol Chem. 2024; 300(4):107141. PMC: 10981121. DOI: 10.1016/j.jbc.2024.107141. View

20.

Yan T, Ma X, Zhou K, Cao J, Tian Y, Zheng H . A novel CSN5/CRT O-GlcNAc/ER stress regulatory axis in platinum resistance of epithelial ovarian cancer. Int J Biol Sci. 2024; 20(4):1279-1296. PMC: 10878149. DOI: 10.7150/ijbs.89700. View